CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Clinical Trials Arena
Original article

EAN 2026: NeuroDerm spotlights Onerji fall reduction in advanced Parkinson’s disease

ConferenceOnerjiPositive
AI Analysis

Summary

NeuroDerm presented additional data on Onerji's fall reduction benefits in advanced Parkinson's disease at EAN 2026, potentially differentiating the drug competitively.

Importance:5/10
Sentiment:
0.50
Parkinson's diseaseFall reductionEAN 2026Conference presentation
Related Companies

Read the original article

Published by Clinical Trials Arena on July 1, 2026 10:23 AM

Read Original